Results 251 to 260 of about 106,214 (290)

Gynecomastia Associated with Highly Active Antiretroviral Therapy

The Annals of Pharmacotherapy, 2001
OBJECTIVE: To report four cases of HIV-associated gynecomastia diagnosed during treatment with nucleoside analogs with or without protease inhibitors. CASE SUMMARY: Four HIV-infected patients developed gynecomastia while taking two nucleoside analogs (stavudine combined with lamivudine in 3 patients, stavudine with didanosine in 1 patient) and protease
R, Manfredi, L, Calza, F, Chiodo
openaire   +2 more sources

The oncology impact of highly active antiretroviral therapy

Journal of Oncology Pharmacy Practice, 2007
Objective. To examine the impact of using highly active antiretroviral therapy (HAART) in a human immunodeficiency virus (HIV) infected population on the chemotherapy related costs of treating acquired immunodeficiency (AIDS)-related cancers. Methods.
Richard, Schlichemeyer, Carole, Chambers, M John, Gill   +2 more
openaire   +2 more sources

Virologic and immunologic response to highly active antiretroviral therapy

Current HIV/AIDS Reports, 2002
Highly active antiretroviral therapy (HAART) delays clinical progression by suppressing viral replication, measured by a substantial reduction in HIV RNA, allowing the immune system to reconstitute, measured in most studies by an increase in CD4 cells. These virologic and immunologic consequences do not occur uniformly among HAART users. Markers of HIV
Lisa P., Jacobson, John P., Phair, Traci E., Yamashita   +2 more
openaire   +3 more sources

Highly Active Antiretroviral Therapy

PharmacoEconomics, 2001
The advent of highly active antiretroviral therapy (HAART), including protease inhibitors and/or non-nucleoside reverse transcriptase inhibitors, for the treatment of HIV infection has led to a dramatic decline of morbidity and mortality. The acquisition costs of HAART are substantial. However, these costs are partially offset by reduced inpatient care
P, Sendi, A J, Palmer, A, Gafni, M, Battegay   +3 more
openaire   +2 more sources

Late presenters in the era of highly active antiretroviral therapy

AIDS, 2004
To investigate the characteristics and clinical, immunological and virological outcomes for individuals presenting for care with low CD4 cell counts.Individuals aged > 16 years presenting for care for the first time were identified between 1 January 1996 and 31 December 2002. Late presenters were those with CD4 cell count < 50 x 10(6) cells/l.
Caroline A, Sabin, Colette J, Smith, Helen, Gumley, Gabrielle, Murphy, Fiona C, Lampe, Andrew N, Phillips, Beth, Prinz, Mike, Youle, Margaret A, Johnson   +8 more
openaire   +2 more sources

The relationship of pregnancy to the use of highly active antiretroviral therapy

American Journal of Obstetrics and Gynecology, 2001
Public health agencies have recommended that the criteria for the use of highly active antiretroviral therapy should not be modified because of pregnancy. However, little information has been published with regard to the degree to which these recommendations are being followed.
H, Minkoff, L, Ahdieh, H, Watts, R M, Greenblatt, J, Schmidt, M, Schneider, A, Stek   +6 more
openaire   +2 more sources

Adherence Assessment to Highly Active Antiretroviral Therapy

AIDS Patient Care and STDs, 2001
Adherence to highly active antiretroviral therapy (HAART) is the outcome of a dynamic process of clinical and behavioral interactions. This article reviews factors influencing this process and provides suggestions to enhance adherence to HAART. Interventions to improve adherence to HAART should combine efficacy of treatments with a strong patient ...
openaire   +2 more sources

Neurocognitive dysfunction in the highly active antiretroviral therapy era

Current Opinion in Infectious Diseases, 2012
The aim is to review the recent confirmation of the continued high prevalence of HIV-associated neurocognitive disorders (HAND) despite highly active antiretroviral therapy (HAART) in a large cohort study and to review the recent studies that have begun to address the potential reasons for such persistence.HAND remains prevalent, despite effective ...
Nomvuyo Z, Mothobi, Bruce J, Brew
openaire   +2 more sources

Highly active antiretroviral therapy and cervical intraepithelial neoplasia

AIDS, 2002
Highly active antiretroviral therapy (HAART) has improved HIV prognosis, but its effect on cervical intraepithelial neoplasia (CIN), which is associated with HIV, is uncertain. Among 71 HAART-treated women the prevalence of CIN before HAART was 55%. After a median of 10 months after starting HAART the prevalence had increased to 62% (P = 0.20); 13% of ...
Antonia L, Moore, Caroline A, Sabin, Sara, Madge, Amanda, Mocroft, Wendy, Reid, Margaret A, Johnson   +5 more
openaire   +2 more sources

Highly Active Antiretroviral Therapy-Induced Liver Injury

Current Drug Safety, 2008
With the advent of highly active antiretroviral therapy (HAART), the reduction in overall mortality and morbidity in HIV patients has been accompanied by the emergence of liver disease as a leading cause of death. Elevated liver enzymes may be due to HAART or to other risk factors, including hepatitis co-infection and alcohol use.
Ira, Inductivo-Yu, Maurizio, Bonacini
openaire   +2 more sources